Skip to main content

Prokidney Corp.

PROK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001850270

In the last 90 days, Prokidney Corp. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $99.5M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Prokidney Corp. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of PROK: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders6761−6
Shares40.5M29.4M−11.1M (−27.5%)
Value$185.4M$52.3M−$133.1M (−71.8%)

New holders (14)

Institutions that held Prokidney Corp. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to PROK in Q4 2023
InstitutionSharesValue% of portfolio
Squarepoint Ops LLC207,682$369.7K0.00%
Renaissance Technologies LLC120,000$214.0K0.00%
Engineers Gate Manager LP39,831$70.9K0.00%
Susquehanna International Group, LLP32,196$57.3K0.00%
Marshall Wace, LLP23,300$41.5K0.00%
Walleye Capital LLC21,678$38.6K0.00%
Mariner, LLC17,659$31.4K0.00%
Citadel Advisors LLC14,616$26.0K0.00%
Wexford Capital LP12,580$22.4K0.00%
Alpine Global Management, LLC11,186$19.9K0.01%
Price T Rowe Associates Inc10,485$19.0K0.00%
Advisor Group Holdings, Inc.1,450$2.58K0.00%
LM Advisors LLC127$2260.00%
Fifth Third Bancorp52$930.00%

Sold out (20)

Institutions that held Prokidney Corp. at the end of Q3 2023 and filed for Q4 2023 without it.